NO921050L - Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister - Google Patents

Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister

Info

Publication number
NO921050L
NO921050L NO92921050A NO921050A NO921050L NO 921050 L NO921050 L NO 921050L NO 92921050 A NO92921050 A NO 92921050A NO 921050 A NO921050 A NO 921050A NO 921050 L NO921050 L NO 921050L
Authority
NO
Norway
Prior art keywords
histamine
subject
agent
receptor agonists
receptor
Prior art date
Application number
NO92921050A
Other languages
English (en)
Other versions
NO921050D0 (no
Inventor
Jan Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Estero Anstalt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estero Anstalt filed Critical Estero Anstalt
Publication of NO921050L publication Critical patent/NO921050L/no
Publication of NO921050D0 publication Critical patent/NO921050D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO921050A 1989-09-19 1992-03-18 Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister NO921050D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40935789A 1989-09-19 1989-09-19
PCT/SE1990/000599 WO1991004037A1 (en) 1989-09-19 1990-09-19 Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists

Publications (2)

Publication Number Publication Date
NO921050L true NO921050L (no) 1992-03-18
NO921050D0 NO921050D0 (no) 1992-03-18

Family

ID=23620128

Family Applications (1)

Application Number Title Priority Date Filing Date
NO921050A NO921050D0 (no) 1989-09-19 1992-03-18 Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister

Country Status (12)

Country Link
US (1) US5348739A (no)
EP (1) EP0493468B1 (no)
JP (1) JP2845622B2 (no)
KR (1) KR100195392B1 (no)
AT (1) ATE136786T1 (no)
AU (1) AU640954B2 (no)
CA (1) CA2066728C (no)
DE (1) DE69026620T2 (no)
DK (1) DK0493468T3 (no)
ES (1) ES2087163T3 (no)
NO (1) NO921050D0 (no)
WO (1) WO1991004037A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9300616A (en) * 1992-11-27 1994-06-30 Wellcome Found Enzyme inhibitors
AU709635B2 (en) * 1994-08-08 1999-09-02 Maxim Pharmaceuticals, Inc. Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
KR20010072957A (ko) * 1998-08-24 2001-07-31 추후보정 Ｈ2 수용체 작용제 및 기타 ｔ-세포 활성화제를 사용한ｔ-세포(ｃｄ4+ 및 ｃｄ8+) 활성화 및 보호 방법
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6153113A (en) * 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
CA2377247A1 (en) * 1999-07-16 2001-01-25 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
US20030228277A1 (en) * 2002-03-29 2003-12-11 Gehlsen Kurt R. Use of ROM production and release inhibitors to treat and prevent intraocular damage
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
WO2006039545A2 (en) * 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
KR20070116011A (ko) 2005-02-25 2007-12-06 이노텍 파마슈티컬스 코포레이션 테트라사이클릭 아미노 및 카복사미도 화합물 및 이의 이용방법
JP2009506060A (ja) 2005-08-24 2009-02-12 イノテック ファーマシューティカルズ コーポレイション インデノイソキノリノン類縁体及びそれらの使用方法
CA2677046A1 (en) 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
EP2419099A2 (en) * 2009-04-16 2012-02-22 Epicept Corporation Composition and use of n-alpha-methylhistamine
US9617517B2 (en) 2011-05-02 2017-04-11 National University Corporation Kumamoto University Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound
US20200222505A1 (en) * 2017-06-29 2020-07-16 Immune Pharmaceuticals, Inc. Methods of delaying and preventing acute myeloid leukemia relapse
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
ATE136786T1 (de) 1996-05-15
EP0493468B1 (en) 1996-04-17
DK0493468T3 (da) 1996-08-26
AU640954B2 (en) 1993-09-09
AU6419190A (en) 1991-04-18
CA2066728C (en) 2001-12-25
KR920703078A (ko) 1992-12-17
ES2087163T3 (es) 1996-07-16
DE69026620D1 (de) 1996-05-23
CA2066728A1 (en) 1991-03-20
WO1991004037A1 (en) 1991-04-04
DE69026620T2 (de) 1996-10-02
JPH05504548A (ja) 1993-07-15
NO921050D0 (no) 1992-03-18
JP2845622B2 (ja) 1999-01-13
KR100195392B1 (ko) 1999-06-15
US5348739A (en) 1994-09-20
EP0493468A1 (en) 1992-07-08

Similar Documents

Publication Publication Date Title
NO921050L (no) Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister
Goldstein et al. The role of interferon in cancer therapy: a current perspective
DK0565587T3 (da) Virkning af N,N,N-trimethylsphingosin på proteinkinase-C-aktivitet, melanomcellevækst in vitro, metastatisk potentiale in vivo og human blodpladeaggregation.
Miller Intratumor immunologic heterogeneity
Byfield et al. Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
ES8502405A1 (es) Un metodo para producir una emulsion acuosa de perfluorocarburo
FR2699176B1 (fr) Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
Chiodoni et al. Different requirements for α‐galactosylceramide and recombinant IL‐12 antitumor activity in the treatment of C‐26 colon carcinoma hepatic metastases
NO944214D0 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
Shimizu et al. Effects of a single injection of anti‐asialo GM1 serum on natural cytotoxicity and the growth of a regressive colonic tumor in syngeneic rats
PH13417A (en) Thiourea and guanidine derivative having actively as hestamine h2 receptor antagonists and pharmaceuas histamine h2 receptor artagonists and pharmaceutical composition
Alpaugh et al. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon
Maeda et al. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma
DK72591D0 (da) Hidtil ukendt s-timolol-derivat samt fremgangsmaade til fremstilling deraf
Chao et al. Effect of indomethacin on tumor-infiltrating lymphocytes of a spontaneously developed murine mammary adenocarcinoma
KR850006429A (ko) 새로운 시아노이미다졸 누클레오시드 유도체 및 그 제조방법
Pereira et al. The effect of nicotinamide adenine dinucleotide on lipolysis in adipose tissue in vitro
JPH07196490A (ja) 癌転移抑制剤
Rochlitz et al. Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors
Gold et al. Autolymphocyte therapy—I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes
Robins Purine nucleoside 3′, 5′-cyclic monophosphates as hormonal modulators of cellular proliferation, metastases and lymphocyte response
Puri et al. In vivo treatment with interferon causes augmentation of IL‐2 induced lymphokine‐activated killer cells in the organs of mice
Lentz et al. Phenotypic and functional characteristics of mononuclear cells in ovarian carcinoma tumors
Voltchek et al. Comparative study of the cytostatic effects of Oliphen and Ukrain